Holden Cancer Center joins Caris’ extensive network of leading cancer institutions committed to utilizing clinical data to advance patient care and outcomes
IRVING, Texas, November 16, 2022 – Caris Life Sciences® (Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced today that University of Iowa Holden Comprehensive Cancer Center has joined Caris’ Precision Oncology Alliance™ (POA). The POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research. POA members work together to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers that improve the clinical outcomes for cancer patients.
Holden Cancer Center is Iowa’s only NCI-designated comprehensive cancer center, and has held that designation since 2000. Nearly 1,200 staff and cancer center members, including faculty from 41 academic departments, collaborate to drive Holden’s research, education, and patient-care missions. Holden is the recipient of two NCI Specialized Program of Research Excellence (SPORE) grants, including the first and only neuroendocrine tumor SPORE.
“We are excited about joining forces with experts from around the country as members of this important alliance that is based on the understanding that progress in cancer research is accelerated when we work together,” said George Weiner, M.D., Director of Holden Comprehensive Cancer Center.
“We’re pleased to welcome Holden Cancer Center into the growing Caris Precision Oncology Alliance network,” said Chadi Nabhan, M.D., MBA, FACP, Chairman of the Caris Precision Oncology Alliance. “Collaborating with top researchers, investigators, and physicians at the University of Iowa Cancer Center will lead to more cutting-edge precision oncology research that is destined to improve outcomes of all patients affected with cancer.”
The Caris Precision Oncology Alliance includes 74 cancer centers and academic institutions. These institutions have early access to the extensive database and artificial intelligence platform within Caris to establish evidence-based standards for cancer profiling and advance research in cancer precision medicine. By leveraging the comprehensive genomic, transcriptomic and proteomic profiling available through Caris molecular profiling, Caris seeks to provide this network with the ability to prioritize therapeutic options and determine which clinical trial opportunities may benefit their patients. POA members are also able to integrate with a growing portfolio of biomarker directed trials sponsored by biopharma. Additionally, as a member of the POA, institutions have access to Caris CODEai™, the most comprehensive data solution in the industry with cancer treatment information and clinical outcomes data for over 275,000 patients covering over 1 million data points per patient.
About Caris Life Sciences
Caris Life Sciences® (Caris) is the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare and improve patient outcomes. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris has created the large-scale clinico-genomic database and cognitive computing needed to analyze and unravel the molecular complexity of disease. This information provides an unmatched resource and the ideal path forward to conduct the basic, fundamental research to accelerate discovery for detection, diagnosis, monitoring, therapy selection and drug development to improve the human condition.
With a primary focus on cancer, Caris’ suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps patients, physicians and researchers better detect, diagnose and treat patients. Caris’ latest advancement is a blood-based, circulating nucleic acids sequencing (cNAS) assay that combines comprehensive molecular analysis (Whole Exome and Whole Transcriptome Sequencing from blood) and serial monitoring – making it the most powerful liquid biopsy assay ever developed.
Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Denver, Tokyo, Japan and Basel, Switzerland. Caris provides services throughout the U.S., Europe, Asia and other international markets. To learn more, please visit CarisLifeSciences.com or follow us on LinkedIn.